Debt Financing
Tevogen pays off Patel loan in stock and gives CEO 50 million shares
Tevogen cut the repayment price on its Patel Family credit line to $7.40 from $75.00 and settled $7.4 million in stock. The same day CEO Ryan Saadi got 50,000,000 restricted shares, lifting his voting power to about 90.9%.

Tevogen Inc. (Nasdaq: TVGN) cleared its $7.4 million credit line from The Patel Family, LLP in stock on November 2, 2026, and on the same day handed Chief Executive Officer and Chairperson Ryan Saadi a restricted stock award of 50,000,000 shares. After the grant and the repayment, the company says Saadi held about 90.9% of the voting power of the 67,880,267 shares outstanding. The award alone is about 74% of that share count. The shares vest only if Tevogen reaches $1.0 billion in aggregate revenue by December 31, 2031, but Saadi can vote them now, and the company has not yet generated any revenue. In our reading, that leaves other holders with almost no say over the company. November 3 8-K
The loan amendment
On October 27, Tevogen signed a First Amendment to Loan Agreement with The Patel Family, LLP. It amends a loan agreement dated June 6, 2024, which gave the company an unsecured line of credit of up to $36.0 million and a contingent private placement option the filing calls the PIPE. November 3 8-K
The amendment moves the end of the borrowing period from May 31, 2027 to May 31, 2029. It drops the $1.0 million cap on each monthly draw. Tevogen can now borrow at least $1.0 million a month, or a smaller or larger amount it names, with total post-amendment borrowings capped at $28.6 million.
The central change is the share price. Shares issued to pay principal and interest, including interest accrued but unpaid on the amendment date, are now priced at a fixed $7.40. The old agreement used a $75.00 price for interest shares and a $75.00 floor on principal payments. The amendment also fixes the lender's beneficial ownership limit at 9.99% (the lender can no longer change it by notice), and resets the measurement date for the 19.99% issuance cap to the amendment date.
The repayment in stock
Principal outstanding on the amendment date was $7.4 million. Tevogen chose to repay all of it, plus $177,880 of accrued and unpaid interest, in common stock. On November 2 it issued the lender 1,000,000 principal shares and 23,733 interest shares, which the filing says eliminated all outstanding liabilities under the agreement. Before the amendment the lender had received 20,000 commitment shares and 5,394 interest shares on a post-reverse-split basis. November 3 8-K
No cash left the company. In our reading, the cost has moved to shareholders, because the new $7.40 price is about a tenth of the old $75.00 terms and every future draw can now be settled in stock at that level. The filing estimates that if Tevogen borrows the full $28.6 million, makes no prepayments, pays the maximum 7.00% annual rate, keeps each draw for its full 48-month term, pays all principal in shares in one payment and completes the PIPE at its minimum price, up to about 4.99 million more shares could be issued, subject to the ownership limit and the issuance cap.
The only counterparty named is The Patel Family, LLP, which represented that it is an accredited investor. The shares were issued without registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The filing names no placement agent, arranger, financial advisor or counsel to either side. The latest 10-Q says KRHP LLC, which has given Tevogen grants and committed to another $7.0 million grant, is affiliated with the Patel Family. 10-Q for June 30, 2026
Why Tevogen leans on this lender
Tevogen reported cash of $1,082,155 at June 30, 2026, a net loss of $11.2 million for the first half and $5.7 million of cash used in operations. It had a stockholders' deficit of $8.9 million, and the loan balance stood at $6.4 million. Management said that cash, plus the Patel loan and the remaining KRHP grant commitment, would fund operations. Tevogen says it has not generated any revenue and does not expect product revenue unless it wins approval for TVGN 489 or another candidate. 10-Q
The second grant in seven weeks
The November award follows a September 14 grant of 8,000,000 restricted shares to Saadi and 750,000 to Chief Financial Officer Kirti Desai, tied to $1.0 billion of aggregate revenue by September 30, 2031. Right after that grant, Saadi owned 74.4% of 15,736,540 shares outstanding. The board says the new award keeps Saadi's "continuing significant voice" in strategy. It is forfeited if the target is missed or his service ends first. September 16 8-K
Director Susan Podlogar resigned with immediate effect on November 2, the day of the grant. The board shrank from six to five members and put director Lindee Goh on the Audit Committee. The filing gives no reason for her departure. November 4 8-K
Next to read: the resale registration for the 1,000,000 principal shares, due within 15 calendar days of issuance, and the third-quarter 10-Q, the first periodic report since the amendment and the grant.
Investor Chat
Loading posts…
aibio